Laura Panjwani

The investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with <em>FLT3-ITD&ndash;</em>positive relapsed acute myeloid leukemia.

The combination of nilotinib and trametinib proved to be synergistic in <em>BRAF/NRAS</em> wild-type melanoma,&nbsp;according to a recent study presented at the 2016 Society for Melanoma Research Congress.

Tanios Bekaii-Saab, MD, discusses&nbsp;questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.

Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.

Women who have been vaccinated against HPV can undergo less-intensive cervical cancer screening than is currently recommended.

Findings of a new study revealed that less than half of patients with advanced cervical cancer are receiving all 3 of the therapies considered standard of care (SOC) for the disease.

Immunotherapy has potential in anaplastic thyroid cancer, but it presents a challenge because of the length of time it takes to have an effect. Maria Cabanillas, MD, discusses an upcoming clinical trial that is combining immunotherapy with targeted therapy, that may offer a solution.

The CheckPoints, which are considered the official house band of the Society for Immunotherapy of Cancer (SITC), performs every year at the annual meeting, as well as at a SITC sponsored event at the ASCO annual meeting each year.

New findings from a study suggest it is unlikely that any single gene can predict response to targeted therapy for patients with HER2-positive breast cancer. Instead, gene networks&mdash; specifically those involving PI3 kinase &mdash;may provide a clearer picture of patient outcomes.

James Allison, PhD, discusses exciting advancements in immunotherapy combinations, the potential synergistic effects of radiation with immunotherapies, and considerations that must be made when combining other agents with immunotherapy.

Robert S. Alter, MD discusses optimal sequencing for bladder cancer agents and how he determines the appropriate treatment for patients.

In patients with metastatic colorectal cancer (mCRC), the correlation between tumor location and improved survival varies based on stage of disease, according to a study.

An expert discusses the potential role for immunotherapy in frontline head and neck cancer, as well as the possible benefit of using it in combination with standard treatments, including radiation and chemotherapy.

Mutation discordance between primary and metastatic sites in colorectal cancer (CRC) may occur more often than previously understood, opening the door for potential new therapeutic approaches to treating the disease.

For the first time, Physicians&rsquo; Education Resource (PER&reg;) will host 2 European conferences, providing&nbsp;more opportunities for oncology professionals worldwide to learn and collaborate with leading experts in the fields.

Optune, a noninvasive device that delivers tumor-treating fields to the brain, provides oncologists, specifically those who treat glioblastoma multiforme, an opportunity to apply technology as part of their standard treatment regimen.

ASCO-CAP recently released new guidelines for the use of FISH testing for HER2 in breast cancer, due to discrepancies in HER2-testing results.

Katherine Thornton, MD, discusses the potential that immunotherapy agents could have in sarcoma, as well as the role of genomic profiling in understanding the patients who may benefit from select treatments.

William G. Wierda, MD, PhD,&nbsp;discusses which groups of CLL patients may benefit from ibrutinib versus chemoimmunotherapy and clinical trials that may provide further clarification.

<em>Targeted Oncology</em> speaks with Shaji Kumar, MD, to understand the roles that the new criteria for response and minimal residual disease (MRD) assessment in multiple myeloma&nbsp;and what role MRD testing will play going forward in multiple myeloma.<br /> &nbsp;

James Hsieh, MD, PhD, discusses the 3 &quot;eras&quot; in the treatment of kidney cancer.

Distinguishing between polycythemia vera (PV) and essential thrombocythemia (ET) is key for the effective treatment of both diseases, said Heinz Gisslinger, MD, of the Medical University of Vienna.

Chau T. Dang, MD&nbsp;discusses several recent trials investigating novel treatment approaches for patients with HER2-positive breast cancer.

<div>Though Nivolumab (Opdivo) and ipilimumab (Yervoy) have demonstrated considerable success in the field of metastatic melanoma as both single agents and in combination, questions remain regarding sequencing the agents and the high toxicities that often occur when the 2 immunotherapies are used together.<br /> &nbsp;</div>

Melanoma research is rapidly advancing, explains Jedd D. Wolchok, MD, PhD, particularly with immunotherapy.<br /> <br /> &nbsp;

Not all gastroesophageal junction cancers should be treated the same, according to Richard J. Bold, MD.

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non-small cell lung cancer, although they are not commonly considered while doing mutation testing.

The FDA approval of pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma in August 2016 was extremely significant for this patient population, which previously had limited options following progression on a platinum-based chemotherapy.

A therapy that provides an impressive and durable benefit has been mostly out of reach in the primary brain cancer space, particularly for glioblastoma.

Today, the field of melanoma is virtually unrecognizable from what it was not that long ago.